The bioavailability problem Absorption comparison: Injection: 80-100% bioavailability (nearly all absorbed) Nasal spray: 30-70% bioavailability (varies by peptide) Oral: 0-5% bioavailability (most peptides destroyed) Why nasal lower than injection: Must penetrate nasal mucosa (barrier) Some drips down throat (swallowed = lost) Variable absorption efficiency Technique-dependent Individual variation high What this means: You need MORE peptide via nasal spray Typically 2-3x higher dose than injection Example: 1mg injection = 2-3mg nasal Increases cost significantly But still cheaper/easier than injection for some Conversion guidelines by peptide PT-141: Injection: 1.5-2mg typical dose Nasal equivalent: 3-5mg Conversion ratio: 2-3x Semax: Designed for nasal use (no conversion needed) Standard nasal dose: 200-600mcg per spray 2-3 sprays per nostril typical Follow product guidelines BPC-157 (if attempting nasal): Injection: 250-500mcg Nasal (estimated): 750-1500mcg But: Injection or oral likely better Nasal BPC-157 not well-studied General conversion approach: Start with 2-3x injection dose Assess results after 2-3 uses Increase by 25-50% if weak effects Find minimum effective nasal dose Individual variation significant Cost implications: Using 2-3x more peptide = 2-3x cost Nasal spray more expensive per dose Trade-off: Convenience vs cost Worth it for needle-phobic Not worth it if injections acceptable Use peptide cost calculator to compare routes
Our peptides are scientifically developed to support anti-aging, skin brightening, collagen stimulation, and overall skin healthideal for cosmetic manufacturers, skincare brands, and R&D labs
With studies characterising reduced infarct size, improved cardiac function, promotion of cardiac progenitor cell migration, cardiomyocyte survival through PI3K/Akt anti-apoptotic signalling, and stimulation of new vessel formation in infarcted myocardium
Lu and P.A
In PD specifically, curcumin has improved motor behavior and dopaminergic neuron survival in some rodent studies, and it continues to be investigated in preclinical and early clinical settings (such as trials of curcumin formulations or analogues with improved bioavailability) (80)
pmid:28044066
